Publications by authors named "Mousa Alahmari"
Objective: Duchenne muscular dystrophy (DMD) is a rare X-linked neurodegenerative disorder caused by mutations in the gene. This study examined the efficacy and safety of ataluren, the first oral treatment for DMD with nonsense mutations (nmDMD), in patients in the Middle East.
Methods: This retrospective longitudinal study assessed the outcomes of seven boys with nmDMD who received treatment with ataluren and follow-up at a single center since 2016.
Article Synopsis
- Tumor lysis syndrome (TLS) is a serious condition associated with cancer that can lead to high uric acid levels, requiring treatment with rasburicase, which faced shortages during the COVID-19 pandemic.!* -
- This study aimed to evaluate the effectiveness of a fixed 3 mg dose of rasburicase in reducing uric acid levels in adult cancer patients, focusing on results observed at 24 and 48 hours post-treatment.!* -
- Results showed that 88% of patients treated with the fixed dose experienced normal uric acid levels within 24 hours, and 100% of those receiving rasburicase for prevention reached normal levels, confirming the fixed dose's effectiveness.!*
Case: We present a case of an 8-year-old boy with classical bladder exstrophy and a neglected right hip dislocation, exemplifying the risk of missed developmental dysplasia of the hip (DDH) in patients with exstrophy requiring careful orthopaedic oversight.
Conclusions: When treating patients with bladder exstrophy, physicians and surgeons should be vigilant not to miss associated DDH. If this condition requires surgical treatment, preoperative planning with computed tomography scans is vital to uncovering the complexities arising from abnormal pelvic and acetabular anatomy and ensuring successful treatment outcomes.
Objective: Prescribing a drug for a child is not an easy task and requires using the best available evidence as a guide, especially when a drug is used off-label. The practice of prescribing a drug for off-label use is fairly widespread worldwide. The FDA does not regulate prescribing patterns or practices of individual practitioners and, therefore, allows off-label use.
View Article and Find Full Text PDFWe report a unique wrong implant error during bilateral total knee replacement procedure in 72-year-old woman with bilateral knee osteoarthritis that failed conservative treatment. Patient has severe bilateral knee pain. Examination showed full range of motion.
View Article and Find Full Text PDF